CN100335461C - 芳基磺酰基苯胺脲 - Google Patents

芳基磺酰基苯胺脲 Download PDF

Info

Publication number
CN100335461C
CN100335461C CNB99811233XA CN99811233A CN100335461C CN 100335461 C CN100335461 C CN 100335461C CN B99811233X A CNB99811233X A CN B99811233XA CN 99811233 A CN99811233 A CN 99811233A CN 100335461 C CN100335461 C CN 100335461C
Authority
CN
China
Prior art keywords
alkyl
hydrogen
compound
assorted
assorted alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB99811233XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1319088A (zh
Inventor
乔纳森·B·豪兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Roa Kwesi Shane Co
Amgen SF LLC
Amgen Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of CN1319088A publication Critical patent/CN1319088A/zh
Application granted granted Critical
Publication of CN100335461C publication Critical patent/CN100335461C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
CNB99811233XA 1998-09-23 1999-09-21 芳基磺酰基苯胺脲 Expired - Fee Related CN100335461C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10088898P 1998-09-23 1998-09-23
US60/100,888 1998-09-23

Publications (2)

Publication Number Publication Date
CN1319088A CN1319088A (zh) 2001-10-24
CN100335461C true CN100335461C (zh) 2007-09-05

Family

ID=22282047

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB99811233XA Expired - Fee Related CN100335461C (zh) 1998-09-23 1999-09-21 芳基磺酰基苯胺脲

Country Status (23)

Country Link
US (3) US6214880B1 (https=)
EP (1) EP1115701B1 (https=)
JP (1) JP3926983B2 (https=)
KR (1) KR100642184B1 (https=)
CN (1) CN100335461C (https=)
AT (1) ATE240940T1 (https=)
AU (1) AU747663B2 (https=)
BR (1) BR9913903A (https=)
CA (1) CA2343204C (https=)
CZ (1) CZ2001934A3 (https=)
DE (1) DE69908156T2 (https=)
DK (1) DK1115701T3 (https=)
EA (1) EA003924B1 (https=)
ES (1) ES2194547T3 (https=)
HU (1) HUP0103884A3 (https=)
IL (2) IL142066A0 (https=)
NO (1) NO20011453L (https=)
NZ (1) NZ510435A (https=)
PL (1) PL198394B1 (https=)
PT (1) PT1115701E (https=)
SK (1) SK284757B6 (https=)
WO (1) WO2000017159A1 (https=)
ZA (1) ZA200102033B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104797429A (zh) * 2012-11-21 2015-07-22 日本曹达株式会社 使用了非酚类化合物的记录材料

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508644D0 (en) * 1995-04-28 1995-06-14 Exxon Chemical Patents Inc Fuel compositions
ES2194547T3 (es) * 1998-09-23 2003-11-16 Tularik Inc Arilsulfonanilida-ureas.
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
AU775305B2 (en) * 1999-07-29 2004-07-29 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound
US6664259B2 (en) 2000-03-16 2003-12-16 Smithkline Beecham Corporation Il-8 receptor antagonists
AR031098A1 (es) * 2000-03-16 2003-09-10 Smithkline Beecham Corp Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina
UY26627A1 (es) * 2000-03-24 2001-09-28 Smithkline Beecham Corp Antagonistas de receptores de il-8
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002039958A2 (en) 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU2002306604B2 (en) 2001-02-28 2007-09-13 Onconova Therapeutics, Inc. N-(Aryl)-2-arylethenesulfonamides and therapeutic uses thereof
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
JP4434744B2 (ja) * 2002-01-30 2010-03-17 アムジェン インコーポレイテッド アリールスルホンアミドベンジル化合物
US7112606B2 (en) * 2002-01-30 2006-09-26 Amgen Inc. Heterocyclic arylsulfonamidobenzylic compounds
EP1534284B1 (en) 2002-02-28 2011-07-27 Temple University - Of The Commonwealth System of Higher Education Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
EP1660459A2 (en) * 2003-08-12 2006-05-31 Amgen inc. Arylsulfonamidobenzylic compounds
US20050124664A1 (en) * 2003-10-30 2005-06-09 Eric Sartori Urea thiadiazole inhibitors of plasminogen activator inhibior-1
US20050154455A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
US20060062822A1 (en) * 2004-09-21 2006-03-23 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20070027530A1 (en) * 2005-07-26 2007-02-01 Medtronic Vascular, Inc. Intraluminal device, catheter assembly, and method of use thereof
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070067020A1 (en) * 2005-09-22 2007-03-22 Medtronic Vasular, Inc. Intraluminal stent, delivery system, and a method of treating a vascular condition
AR060562A1 (es) * 2006-04-21 2008-06-25 Smithkline Beecham Corp Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas.
US8097626B2 (en) * 2006-04-21 2012-01-17 Glaxosmithkline Llc IL-8 receptor antagonists
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
AR061571A1 (es) * 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
WO2009088549A2 (en) * 2007-10-19 2009-07-16 The Board Of Regents Of The University Of Texas System Methods of inhibiting bacterial virulence and compounds relating thereto
EP2385831A4 (en) * 2009-01-09 2014-03-26 Uab Research Foundation SMALL MOLECULAR HEMMER OF NADS, NAMNAT AND NMNAT
US9444712B2 (en) 2012-11-21 2016-09-13 Cisco Technology, Inc. Bandwidth on-demand services in multiple layer networks
JPWO2017170826A1 (ja) * 2016-03-30 2019-02-14 味の素株式会社 グルカゴン様ペプチド−1受容体作用増強活性を有する化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2456731A1 (fr) * 1979-05-16 1980-12-12 Choay Sa Nouveaux derives substitues d'ary
EP0472053A2 (en) * 1990-08-20 1992-02-26 Eisai Co., Ltd. Sulfonamide derivatives
WO1997030677A2 (en) * 1996-02-22 1997-08-28 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
WO1998005315A1 (en) * 1996-07-19 1998-02-12 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1955207A (en) 1931-09-16 1934-04-17 Ig Farbenindustrie Ag Mothproofing agent
DE622494C (de) 1932-01-03 1935-11-29 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Mono- bzw. Polynitropolysulfonen und deren Reduktionsprodukten
US2358365A (en) 1940-08-03 1944-09-19 Parke Davis & Co Sulphonamide derivatives and process for obtaining the same
US2402623A (en) 1943-06-24 1946-06-25 Rohm & Haas Nu-nitroaryl haloarylsulphonamides
CH362688A (de) 1957-09-10 1962-06-30 Geigy Ag J R Verfahren zur Herstellung von neuen Arylsulfonarylamiden
GB938890A (en) 1961-02-03 1963-10-09 Boots Pure Drug Co Ltd New fungicidal compositions and compounds
CH504416A (de) 1966-12-05 1971-03-15 Ciba Geigy Ag Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
GB1242057A (en) 1968-07-04 1971-08-11 Ici Ltd Derivatives of 4-hydroxytetrafluoropyridine and the use thereof as plant growth regulators
NL174644C (nl) 1970-04-13 1984-07-16 Minnesota Mining & Mfg Werkwijze ter bereiding van een herbicide verbinding; tevens werkwijze voor de bereiding van een preparaat met herbicide werking.
DE3623184A1 (de) 1986-07-10 1988-01-14 Kali Chemie Ag Verfahren zur herstellung von n-fluorsulfonamiden
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
DE3804990A1 (de) 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
DE3905075A1 (de) 1989-02-18 1990-08-30 Hoechst Ag Benzolsulfonamide und verfahren zu ihrer herstellung
FR2645537B1 (fr) 1989-04-05 1994-03-04 Fabre Medicament Pierre Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5189211A (en) 1990-08-01 1993-02-23 Taisho Pharmaceutical Co., Ltd. Sulfonamide derivatives
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
WO1999024407A1 (en) 1997-11-10 1999-05-20 Array Biopharma, Inc. Compounds which inhibit tryptase activity
ATE282591T1 (de) 1997-12-23 2004-12-15 Warner Lambert Co Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
ES2194547T3 (es) * 1998-09-23 2003-11-16 Tularik Inc Arilsulfonanilida-ureas.
AU775305B2 (en) * 1999-07-29 2004-07-29 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2456731A1 (fr) * 1979-05-16 1980-12-12 Choay Sa Nouveaux derives substitues d'ary
EP0472053A2 (en) * 1990-08-20 1992-02-26 Eisai Co., Ltd. Sulfonamide derivatives
WO1997030677A2 (en) * 1996-02-22 1997-08-28 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
WO1998005315A1 (en) * 1996-07-19 1998-02-12 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104797429A (zh) * 2012-11-21 2015-07-22 日本曹达株式会社 使用了非酚类化合物的记录材料

Also Published As

Publication number Publication date
IL142066A0 (en) 2002-03-10
ATE240940T1 (de) 2003-06-15
PT1115701E (pt) 2003-09-30
HUP0103884A3 (en) 2002-11-28
US20030207864A1 (en) 2003-11-06
ZA200102033B (en) 2001-09-12
DE69908156D1 (de) 2003-06-26
DK1115701T3 (da) 2003-06-23
NO20011453L (no) 2001-05-23
AU6058099A (en) 2000-04-10
AU747663B2 (en) 2002-05-16
EA003924B1 (ru) 2003-10-30
EP1115701A1 (en) 2001-07-18
KR20010079892A (ko) 2001-08-22
IL142066A (en) 2006-07-05
SK284757B6 (sk) 2005-11-03
PL346797A1 (en) 2002-02-25
SK4002001A3 (en) 2001-09-11
US6214880B1 (en) 2001-04-10
HK1038913A1 (en) 2002-04-04
HUP0103884A2 (hu) 2002-05-29
DE69908156T2 (de) 2003-12-24
BR9913903A (pt) 2001-07-03
WO2000017159A1 (en) 2000-03-30
EP1115701B1 (en) 2003-05-21
KR100642184B1 (ko) 2006-11-10
US7060718B2 (en) 2006-06-13
US20010027211A1 (en) 2001-10-04
CN1319088A (zh) 2001-10-24
ES2194547T3 (es) 2003-11-16
CZ2001934A3 (cs) 2001-08-15
EA200100376A1 (ru) 2001-08-27
US6583165B2 (en) 2003-06-24
NO20011453D0 (no) 2001-03-22
CA2343204C (en) 2008-04-29
JP3926983B2 (ja) 2007-06-06
JP2002526472A (ja) 2002-08-20
NZ510435A (en) 2003-04-29
CA2343204A1 (en) 2000-03-30
PL198394B1 (pl) 2008-06-30

Similar Documents

Publication Publication Date Title
CN100335461C (zh) 芳基磺酰基苯胺脲
CN108314663B (zh) 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途
EP1318978B1 (en) N-acylsulfonamide apoptosis promoters
JP4084189B2 (ja) 尿素の新誘導体、それらの製造方法、それらの薬剤としての使用、製薬組成物及び新規な用途
JP5426560B2 (ja) 新規なヒストンデアセチラーゼインヒビター、その調製方法および使用
CZ20013248A3 (cs) Nové sloučeniny a prostředky jako inhibitory proteázy
CN1649582A (zh) 氨基-甲基取代的四环素类化合物
EA005210B1 (ru) Сульфонамиды гидроксидифенилмочевины в качестве антагонистов рецептора ил-8
JP2013537535A (ja) Statタンパク質の阻害剤としての、置換2−ヒドロキシ−4−(2−(フェニルスルホンアミド)アセトアミド)安息香酸類似体
CZ159098A3 (cs) Inhibitory metaloproteinázy a farmaceutický prostředek
WO2013006734A1 (en) Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
KR20210044802A (ko) 1-메틸-4-[(4-페닐페닐)설포닐메틸]사이클로헥시아놀 및 1-메틸-4-[[4-(2-피리딜)페닐]설포닐메틸]사이클로헥사놀 화합물 및 이의 치료학적 용도
KR20180134675A (ko) 시클로프로필아민 유도체 화합물 및 이의 용도
RU2382029C2 (ru) Новые производные циклогексана
EP3628664A1 (en) Irreversible inhibitors of kras g12c mutant
CN105228609A (zh) 新的转录因子调节剂
JPH10195037A (ja) フェノール誘導体
WO2019091046A1 (zh) 一种来那度胺的衍生物的制备方法与应用
CN109796418B (zh) 含有4-苯基-1,2,3-三氮唑的苯丙氨酸衍生物及其制备方法与应用
EP1285911A2 (en) Arylsulfonanilide ureas
HK1038913B (en) Arylsulfonanilide ureas
MXPA01002717A (es) Ureas de arilsulfonanilida

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: AMGEN CO., LTD.

Free format text: FORMER OWNER: EMINGEN SF CO.,LTD.

Effective date: 20081010

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: AROAQURSIC CO., LTD.

Free format text: FORMER NAME OR ADDRESS: FIGURE LARIC CO.,LTD.

Owner name: EMINGEN SF CO.,LTD.

Free format text: FORMER NAME OR ADDRESS: AROAQURSIC CO., LTD.

CP03 Change of name, title or address

Address after: California, USA

Patentee after: A Roa Kwesi Shane Co.

Address before: California, USA

Patentee before: Tularik Inc.

Address after: California, USA

Patentee after: Amgen company SF

Address before: California, USA

Patentee before: A Roa Kwesi Shane Co.

TR01 Transfer of patent right

Effective date of registration: 20081010

Address after: California, USA

Patentee after: Amgen Limited by Share Ltd.

Address before: California, USA

Patentee before: Amgen company SF

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070905

Termination date: 20091021